Hepatitis C independently raised the risk of kidney disease and osteoporosis or fracture in an analysis of 5,000 people with HIV.
Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.
The first case of Fanconi syndrome associated with PrEP was reported in a poster at the 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV.
Cardiovascular disease, impaired renal function and diabetes all predicted cognitive impairment or performance in HIV-positive men with an undetectable viral load in Amsterdam's AGEhIV cohort.
Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.
For Injection Drug Users With HIV, Higher Risk of Liver/Kidney Disease -- But Not Other Non-AIDS Ills
Compared with HIV-positive people who do not inject drugs, injection drug users ran higher risks of liver or kidney disease in a 5,490-person U.S. comparison.
Renal adverse events and fractures proved rare among people taking tenofovir disoproxil fumarate (TDF) as part of a single-tablet regimen in a large U.S. database of insured patients.
Starting antiretroviral therapy with a ritonavir (Norvir)-boosted protease inhibitor resulted in a higher incidence of chronic kidney disease (CKD), whether or not the regimen included tenofovir disoproxil fumarate (TDF, Viread), according to a recen...
Three studies offer reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also that older people and those with the best adherence might need to b...